NCT02446093Phase 2Unknown

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Study sponsor: Candel Therapeutics, Inc. · CADL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12Estimated
Enrollment · participants54Estimated
Source updated2024-01-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview